We speculate that the PDGFR expression, along with the Q472H VEGFR2 variant and the mutation‐mediated BRAF activation, might have a proangiogenic role in pediatric AF, favoring a response to multitarget anti‐angiogenic agents found active in the adult counterpart 27, 28. The gene discussed is PDGFRB; the disease is atrial fibrillation.